Early stage and long term treatment of multiple sclerosis with interferon-β

References

• LublinFDReingoldSCDefining the clinical course of multiple sclerosis: results of an international surveyNeurology1996469079118780061
   PubMed Web of Science ®Google Scholar
• FisnikuLKBrexPAAltmannDRDisability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset multiple sclerosisBrain200813180881718234696
   PubMed Web of Science ®Google Scholar
• Bar-OrAOlivieraEMLAndersonDEMolecular pathogenesis of multiple sclerosisJ Neuroimmunol199910025225910695735
   PubMed Web of Science ®Google Scholar
• ConlonPOksenbergJRZhangJThe immunobiology of multiple sclerosis: an autoimmune disease of the central nervous systemNeurobiol Dis1999614916610408805
   PubMed Web of Science ®Google Scholar
• MartinRStürzebecherCSMcFarlandHFImmunotherapy of multiple sclerosis: Where are we? Where should we go?Nature Immunol2001278578811526386
   PubMed Web of Science ®Google Scholar
• YongVWChabotSStüveOInterferon beta in the treatment of multiple sclerosis: mechanisms of actionNeurology199851692689
   Web of Science ®Google Scholar
• NoronhaAToscasAJensenMAInterferon β decreases T-cell activation and interferon γ production in multiple sclerosisJ Neuroimmunol1993461451548360326
   PubMed Web of Science ®Google Scholar
• Dhib-JalbutSMechanisms of action of interferons and glatiramer acetate in multiple sclerosisNeurology200258S3S911971121
   PubMed Web of Science ®Google Scholar
• GraberJJFordDZhanMCytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI responseJ Neuroimmunol200718516817417328965
   PubMed Web of Science ®Google Scholar
• StüveODooleyNPUhmJHInterferon β-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9Ann Neurol1996408538639007090
   PubMed Web of Science ®Google Scholar
• LeppertDWaubantEBürkMRInterferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosisAnn Neurol1996408468529007089
   PubMed Web of Science ®Google Scholar
• StoneLAFrankJAAlbertPSThe effect of interferon-β on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosisAnn Neurol1995376116197755356
   PubMed Web of Science ®Google Scholar
• KrausJLingAKHammSInterferon- β stabilizes barrier characteristics for brain endothelial cells in vitroAnn Neurol20045619220515293271
   PubMed Web of Science ®Google Scholar
• CalabresiPATranquillLRDambrosiaJMIncreases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1bAnn Neurol1997416696749153530
   PubMed Web of Science ®Google Scholar
• GraberJZhanMFordDInterferonβ-1a induces increases in vascular cell adhesion molecule: implications for its mode of action in multiple sclerosisJ Neuroimmunol200516116917615748956
   PubMed Web of Science ®Google Scholar
• YongVWDifferential mechanisms of action of interferon-β and glatiramer acetate in MSNeurology20025980280812349849
   PubMed Web of Science ®Google Scholar
• ShariefMKSemraYKSeidiOAInterferon-beta therapy down regulates the anti-apoptosis protein FLIP in T cells from patients with multiple sclerosisJ Neuroimmunol200112110211011730946
   PubMed Web of Science ®Google Scholar
• HamamciogluKRederATInterferon-β regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosisMult Scler20071345947017463069
   PubMed Web of Science ®Google Scholar
• BiernackiKAntelAPBlainMInterferon beta promotes nerve growth factor secretion early in the course of multiple sclerosisArch Neurol20056256356815824253
   PubMed Web of Science ®Google Scholar
• ByskoshPVRederATInterferon-β effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosisMult Scler199612622699345428
   PubMedGoogle Scholar
• RederATVeichkoSYanaguchiKDIFNβ-1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expressionJ Interferon Cytokine Res20082831733118547162
   PubMed Web of Science ®Google Scholar
• StürzebecherSWandingerKPRosenwaldAExpression profiling identifies responder and non-responder phenotypes to interferon-β in multiple sclerosisBrain20031261419142912764062
   PubMed Web of Science ®Google Scholar
• YamaguchiKDRudermanDLCrozeEIFN-β-regulated genes show abnormal expression in therapy-naïve relapsing-remitting MS mononuclear cells: gene expression analysis employing all reported protein-protein interactionsJ Neuroimmunol200819511612018279974
   PubMed Web of Science ®Google Scholar
• GoodinDSFrohmanEMGarmanyGPDisease modifying therapies in multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS council for Clinical Practice GuidelinesNeurology20025816917811805241
   PubMed Web of Science ®Google Scholar
• KnoblerRLGreensteinJLJohnsonKPSystemic recombinant human interferon-β treatment of relapsing-remitting multiple sclerosis: Pilot study analysis and six-year follow upJ Interferon Res1993133333408301153
   PubMedGoogle Scholar
• IFNB Multiple Sclerosis Study GroupInterferon beta-1b is effective in relapsing remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trialNeurology1993436626678469319
   PubMed Web of Science ®Google Scholar
• KurtzkeJFRating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)Neurology198333144414526685237
   PubMed Web of Science ®Google Scholar
• PatyDWLiDKBUBC MS/MRI Study GroupInterferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multi-center, randomized, double-blind, placebo-controlled trialNeurology1993436626678469319
   PubMed Web of Science ®Google Scholar
• IFNB Multiple Sclerosis Study Group; University of British Columbia MS/MRI Analysis GroupInterferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trialNeurology19964512771285
   Web of Science ®Google Scholar
• European Study Group on Interferon β-1b in Secondary Progressive MSPlacebo-controlled multicenter randomized trial of interferon β-1b in treatment of secondary progressive multiple sclerosisLancet1998352149114979820296
   PubMed Web of Science ®Google Scholar
• North American Study Group on Interferon beta-1b in Secondary Progressive MSInterferon beta-1b in secondary progressive MSNeurology2004631788179515557491
   PubMed Web of Science ®Google Scholar
• KapposLWeinshenkerBPozzilliCInterferon beta-1b in secondary progressive MS. A combined analysis of the two trialsNeurology2004631779178715557490
   PubMed Web of Science ®Google Scholar
• KapposLPolmanCHFreedmanMSTreatment with interferon beta 1-b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromesNeurology2006a671242124916914693
   PubMed Web of Science ®Google Scholar
• PoserCMPatyDWScheinbergLNew diagnostic criteria for multiple sclerosis: guidelines for research protocolsAnn Neurol1983132272316847134
   PubMed Web of Science ®Google Scholar
• McDonaldWICompstonAEdanGRecommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosisAnn Neurol20015012112711456302
   PubMed Web of Science ®Google Scholar
• KapposLFreedmanMSPolmanCHEffect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3 year follow-up analysis of the BENEFIT studyLancet200737038939717679016
   PubMed Web of Science ®Google Scholar
• JacobsLDCookfairDLRudickRAIntramuscular interferon beta 1-a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)Ann Neurol1996392852948602746
   PubMed Web of Science ®Google Scholar
• RudickRAGoodkinDEJacobsLDImpact of interferon beta-1a on neurologic disability in relapsing multiple sclerosisNeurology1997493583639270562
   PubMed Web of Science ®Google Scholar
• FischerJSPrioreRLJacobsLDNeuropsychological effects of interferon β-1a in relapsing multiple sclerosisAnn Neurol20004888589211117545
   PubMed Web of Science ®Google Scholar
• FisherERudickRASimonJHEight-year follow-up study of brain atrophy in patients with MSNeurology2002591412142012427893
   PubMed Web of Science ®Google Scholar
• ClanetMRadueEWKapposLA randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MSNeurology2002591507151712451189
   PubMed Web of Science ®Google Scholar
• ClanetMKapposLHartungHPInterferon β-1a in relapsing multiple sclerosis: four-year extension of the European IFNβ-1a dose-comparison studyMult Scler20041013914415124757
   PubMed Web of Science ®Google Scholar
• CohenJACutterGRFischerJSBenefit of interferon β-1a on MSFC progression in secondary progressive MSNeurology20025967968712221157
   PubMed Web of Science ®Google Scholar
• FischerJSRudickRACutterGRThe multiple sclerosis functional composite measure (MSFC): an integrated approach to MS clinical outcome assessmentMult Scler1999524425010467383
   PubMed Web of Science ®Google Scholar
• JacobsLDBeckRWSimonJHIntramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosisN Engl J Med200034389890411006365
   PubMed Web of Science ®Google Scholar
• LearySMMillerDHStevensonVLInterferon β-1a in primary progressive MS. An exploratory, randomized, controlled trialNeurology200360445112525716
   PubMed Web of Science ®Google Scholar
• PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study GroupRandomized double-blind placebo controlled study of interferon β-1a in relapsing/remitting multiple sclerosisLancet1998352149815049820297
   PubMed Web of Science ®Google Scholar
• LiDKBPatyDWUBC MS/MRI Analysis Research Group and PRISMS Study GroupMagnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon- β1a in relapsing remitting multiple sclerosisAnn Neurol19994619720610443885
   PubMed Web of Science ®Google Scholar
• PRISMS Study Group; University of British Columbia MS/MRI Analysis GroupPRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MSNeurology2001561628163611425926
   PubMed Web of Science ®Google Scholar
• KapposLTraboulseeAConstantinescuCLong-term subcutaneous interferon beta-1a therapy in patients with relapsing remitting MSNeurology2006b6794495317000959
   PubMed Web of Science ®Google Scholar
• Once Weekly Interferon for MS Study Group (OWIMS)Evidence of interferon β-1a dose response in relapsing-remitting MSNeurology19995367968610489026
   PubMed Web of Science ®Google Scholar
• Secondary Progressive Efficacy Clinical Trial of Recombinant 1-beta-1a in MS (SPECTRIMS) Study GroupRandomized controlled trial of interferon-beta-1a in secondary progressive MS. Clinical ResultsNeurology2001561496150411402106
   PubMed Web of Science ®Google Scholar
• LiDKBZhaoGJPatyDWRandomized controlled trial of interferon-beta-1a in secondary progressive MSNeurology2001561505151311402107
   PubMed Web of Science ®Google Scholar
• ComiFFillipiMBarkhofFEffect of early interferon treatment on conversion to definite multiple sclerosis: a randomized trialLancet20013571576158211377645
   PubMed Web of Science ®Google Scholar
• EillipiMRovarisMIngleseMInterferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomized, double-blind, placebo controlled trialLancet20043641489149615500893
   PubMed Web of Science ®Google Scholar
• DurelliLVerdunEBarberoPEvery other day interferon beta-1b vs once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomized multicenter study (INCOMIN)Lancet20023591453146011988242
   PubMed Web of Science ®Google Scholar
• PanitchHSGoodinDSFrancisGRandomized, comparative study of interferon β1-a treatment regimens in MS: the EVIDENCE TrialNeurology2002591496150612451188
   PubMed Web of Science ®Google Scholar
• PanitchHGoodinDFrancisGBenefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trialJ Neurol Sci2005239677416169561
   PubMed Web of Science ®Google Scholar
• SchwidSRThorpeJShariefMEnhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the evidence studyArch Neurol20056278579215883267
   PubMed Web of Science ®Google Scholar
• Koch-HenriksenNSφrensenPSChristensenTA randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosisNeurology2006661056106016510769
   PubMed Web of Science ®Google Scholar
• WaltherEUHohlfeldRMultiple sclerosis: side effects of interferon beta therapy and their managementNeurology1999531622162710563602
   PubMed Web of Science ®Google Scholar
• LublinFDWhitakerJNEidelmanBHManagement of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conferenceNeurology19964612188559358
   PubMed Web of Science ®Google Scholar
• MunschauerFEKinkelRPManaging side effects of interferon-beta in patients with relapsing-remitting multiple sclerosisClin Ther1997198838939385477
   PubMed Web of Science ®Google Scholar
• BaumKO’LearyCFerrerFCComparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1bMult Scler2007131153116017967843
   PubMed Web of Science ®Google Scholar
• KümpfelTSchwanMPollmächerTTime of interferon-β-1a injection and duration of treatment affect clinical side effects and acute changes of plasma hormone and cytokine levels in multiple sclerosis patientsMult Scler2007131138114517967841
   PubMed Web of Science ®Google Scholar
• RiceGPEbersGCLublinFDIbuprofen treatment versus gradual introduction of interferon β1-b in patients with MSNeurology1999521893189510371541
   PubMed Web of Science ®Google Scholar
• TremlettHLYoshidaEMOgerJLiver injury associated with the β-interferons for MS: a comparison between three productsNeurology20046262863114981183
   PubMed Web of Science ®Google Scholar
• FrancisGSGrumserYAlteriEHepatic reactions during treatment of multiple sclerosis with interferon-β-1a: incidence and clinical significanceDrug Safety20032681582712908850
   PubMed Web of Science ®Google Scholar
• YoshidaEMRasmussenSLSteinbrecherUPFulminant liver failure during interferon-beta treatment of multiple sclerosisNeurology200156141611376205
   PubMed Web of Science ®Google Scholar
• PeriniPCalabreseMBiasiGThe clinical impact of interferon beta antibodies in relapsing-remitting MSJ Neurol200425130530915015010
   PubMed Web of Science ®Google Scholar
• RiceGPPasznerBOgerJThe evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon β-1bNeurology1999521277127910214759
   PubMed Web of Science ®Google Scholar
• RiceGThe significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon betaArch Neurol2001581297129811493173
   PubMed Web of Science ®Google Scholar
• KhanOADhib-JalbutSSNeutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactiveNeurology199851169817029855525
   PubMed Web of Science ®Google Scholar
• GiovannoniGBarbarashOLJaberAReduced immunogenicity with a new formulation of interferon of interferon-beta-1a (Rebif®): 24-week results of a phase IIIb studyMult Scler200612Suppl 1S192
   Google Scholar
• GoodinDSFrohmanEMHurwitzBNeutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyNeurology20076897798417389300
   PubMed Web of Science ®Google Scholar
• BoskovicRWideRWolpinJThe reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohortNeurology20056580781116186517
   PubMed Web of Science ®Google Scholar
• PattiFRussoPPappalardoAPredictors of quality of life among patients with multiple sclerosis: an Italian cross-sectional studyJ Neurol Sci200725212112917188301
   PubMed Web of Science ®Google Scholar
• Bayer Schering Pharma AGBEYOND study: results do not support regulatory filing for Betaferon^®500 μg Press ReleaseLeverkusen, GermanyBayer Schering Pharma AG2007
   Google Scholar
• LublinFDReingoldSCNational Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MSPlacebo-controlled clinical trials in multiple sclerosis: ethical considerationsAnn Neurol20014967768111357961
   PubMed Web of Science ®Google Scholar